Melatonin for primary insomnia

Review article from the Drug & Therapeutics Bulletin. Bottom-line conclusion: Prolonged-release melatonin (?Circadin) is licensed as shortterm (3 weeks) treatment for primary insomnia in patients aged 55 years and over. In contrast to other hypnotic drugs, there appears to be no evidence of dependence, withdrawal effects or rebound insomnia associated with its use. However, while published trials suggest some benefit with Circadin compared with placebo for people with primary insomnia, the limited evidence on efficacy does not provide a convincing basis for recommending its use. Furthermore, Circadin has not been directly compared with other non-drug or drug treatments in published trials. (Source: Neurological Conditions Specialist Library)

Related posts:

1. Melatonin decreases daytime challenging behaviour in persons with intellectual disability and chronic insomnia
2. Melatonin May Be Safe, Effective for Sleep-onset Insomnia in Children With ADHD
3. Is melatonin effective for preventing cluster headache?
4. Health effects of magnetic fields generated from power lines: new clues for an old puzzle.
5. Melatonin Agonist Tasimelteon (VEC-162) for Transient Insomnia After Sleep-Time Shift: Two Randomized Controlled Multicentre Trials.